AI Article Synopsis

  • The EXTRIP Workgroup performed a systematic review to create guidelines for extracorporeal treatments in phenytoin poisoning, using a two-round modified Delphi method to build consensus on recommendations.
  • Out of 51 included articles, the evidence quality was low, primarily consisting of case reports and pharmacokinetic studies, leading to findings that indicated phenytoin's moderate dialyzability.
  • Recommendations suggest ECTR for select cases of severe poisoning, especially in prolonged coma or ataxia, with intermittent hemodialysis preferred; however, ECTR should only be used in specific, serious cases due to the low risk of permanent damage from phenytoin.

Article Abstract

The Extracorporeal Treatments in Poisoning (EXTRIP) Workgroup conducted a systematic literature review using a standardized process to develop evidence-based recommendations on the use of extracorporeal treatment (ECTR) in patients with phenytoin poisoning. The authors reviewed all articles, extracted data, summarized findings, and proposed structured voting statements following a predetermined format. A 2-round modified Delphi method was used to reach a consensus on voting statements, and the RAND/UCLA Appropriateness Method was used to quantify disagreement. 51 articles met the inclusion criteria. Only case reports, case series, and pharmacokinetic studies were identified, yielding a very low quality of evidence. Clinical data from 31 patients and toxicokinetic grading from 46 patients were abstracted. The workgroup concluded that phenytoin is moderately dialyzable (level of evidence = C) despite its high protein binding and made the following recommendations. ECTR would be reasonable in select cases of severe phenytoin poisoning (neutral recommendation, 3D). ECTR is suggested if prolonged coma is present or expected (graded 2D) and it would be reasonable if prolonged incapacitating ataxia is present or expected (graded 3D). If ECTR is used, it should be discontinued when clinical improvement is apparent (graded 1D). The preferred ECTR modality in phenytoin poisoning is intermittent hemodialysis (graded 1D), but hemoperfusion is an acceptable alternative if hemodialysis is not available (graded 1D). In summary, phenytoin appears to be amenable to extracorporeal removal. However, because of the low incidence of irreversible tissue injury or death related to phenytoin poisoning and the relatively limited effect of ECTR on phenytoin removal, the workgroup proposed the use of ECTR only in very select patients with severe phenytoin poisoning.

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ajkd.2015.08.031DOI Listing

Publication Analysis

Top Keywords

phenytoin poisoning
24
phenytoin
9
extracorporeal treatment
8
poisoning
8
extracorporeal treatments
8
treatments poisoning
8
voting statements
8
severe phenytoin
8
expected graded
8
hemodialysis graded
8

Similar Publications

Phenytoin is a well-known anticonvulsant medication that is useful in the management of most seizure disorders. Given the narrow therapeutic index of 10-20 mg/mL, acute phenytoin overdose can occur with either oral or intravenous administration. There is no distinct antidote to phenytoin, and therefore supportive care is the treatment of choice.

View Article and Find Full Text PDF

3D bioprintedepilepsy models for pharmacological evaluation in temporal lobe epilepsy.

Biofabrication

November 2024

Biomanufacturing Center, Department of Mechanical Engineering, Tsinghua University, Beijing 100084, People's Republic of China.

This study introduces a novelmodel for intractable temporal lobe epilepsy (TLE) utilizing 3D bioprinting technology, aiming to replicate the complex neurobiological characteristics of TLE more accurately. Primary neural cell constructs were fabricated and subjected to epileptiform-inducing conditions, fostering synaptic proliferation and neuronal loss. Systematically electrophysiological and immunofluorescent analyses indicated that significant synaptic connectivity and sustained epileptiform activities within the constructs akin to those observed in human epilepsy models.

View Article and Find Full Text PDF

Objective: The aim of this article is to answer three relevant issues: i/What epileptic condition is referred to as subacute encephalopathy with seizures in alcoholics (SESA) syndrome; ii/ Why it can be important to distinguish SESA syndrome in clinical practice and iii/ What do we know about its pathophysiology.

Methods: We reviewed all cases published in the English language from the initial description of the syndrome to the present. All met the previously established criteria for SESA syndrome were included in our analysis.

View Article and Find Full Text PDF

Subacute encephalopathy with seizures in alcoholics (SESA) syndrome.

Seizure

August 2024

Biomedical Research Institute (IDIVAL), Santander, Cantabria 39011, Spain; Department of Intensive Medicine, Marqués de Valdecilla University Hospital, Santander, Cantabria 39008, Spain.

Purpose: To describe four patients with subacute encephalopathy with seizures in alcoholics (SESA) syndrome and to review its clinical, electroencephalogram (EEG), neuroimaging and diagnostic criteria.

Methods: We conducted a retrospective analysis of a series of prospectively collected patients who met the previously established criteria for SESA syndrome. Subsequently, we reviewed all cases published in the English language from the initial description to the present.

View Article and Find Full Text PDF

<b>Background and Objective:</b> Functional Voltage-Gated Sodium Channels (VGSCs) are expressed in metastatic prostate cancer (PCa) cells. A number of <i>in vitro</i> studies have evaluated the effect of functional VGSC expression on the metastatic cell behavior of PCa cells. This study aimed to evaluate the effect of VGSC inhibition on metastatic cell behavior in PCa cells by meta-analysis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!